Last reviewed · How we verify

NCT05970445

Clinical Phenotypic Characteristics of SC26A4

Status unknown Last updated 23 August 2023
What this trial tests

trial in Hearing Loss in 300 participants. Status unknown.

Timeline
15 May 2023
Primary endpoint
1 August 2023
31 August 2023

Quick facts

Lead sponsorChinese PLA General Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment300
Start date15 May 2023
Primary completion1 August 2023
Estimated completion31 August 2023
Sites1 location across China

Conditions studied

Sponsor

Chinese PLA General Hospital

Who can join

Eligibility, any sex, with Hearing Loss or Pendred Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The presence or absence of SC26A4, whether combined with Mondini malformation, and patient age, are important factors affecting the degree of hearing loss in the Chinese population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hearing Loss

Currently open trials in the same condition.

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05970445.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing